Argus keeps a Buy rating and $90 price target on Bio-Techne while naming the stock as one of the firm’s 2024 Top Picks. As the industry pivots from the global COVID-19 pandemic, the company is focused on solutions to develop new gene and cell therapies and genomics-based diagnostics for early detection of prostate cancer and other disease states, the analyst tells investors in a research note, also noting that Bio-Techne’s solutions help speed-up automation and workflow in the discovery lab and reduce operating costs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TECH:
